Navigation Links
Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
Date:11/30/2009

KING OF PRUSSIA, Pa., Nov. 30 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the completion of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines. Results of the safety and tolerability dose escalation study in healthy volunteers confirm the safety of this compound in initial clinical testing.

All 30 enrolled subjects completed the study, including those receiving the highest dose of CPSI-2364 (270 mg), approximately 30 times the dose that animal models predict will be effective. The drug was well-tolerated with a low incidence of mostly mild adverse events.

"We have now demonstrated that CPSI-2364, a more soluble salt form of semapimod, is safe in humans at doses well above those required for efficacy," said Dr. Thais Sielecki, Vice President of Preclinical Development at Cytokine PharmaSciences. "We have also established a target dose range that we believe optimizes the therapeutic index for CPSI-2364 for use in our next stage of clinical testing."

A Phase II study in patients with Crohn's disease is planned for early 2010.

About CPSI-2364

CPSI-2364 is a chemically-modified form of the synthetic guanylhydrozone, semapimod. Semapimod has been shown to inhibit the signal transduction pathways that lead to the production of nitric oxide and important pro-inflammatory cytokines, including TNF-alpha, IL-1, IL-6, and IL-8. Semapimod has demonstrated activity in multiple animal models of inflammation and autoimmune disease, proof-of-concept studies that led to human clinical trials. An intravenous formulation of semapimod was shown to have significant anti-inflammatory activity in Phase II clinical trials in Crohn's disease, psoriasis and ERCP-induced pancreatitis. However, that formulation caused dose-limiting local reactions, such as phlebitis. To overcome this problem, the Company develop
'/>"/>

SOURCE Cytokine PharmaSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Cytokine Announces Oral Efficacy of Anti-Cytokine Semapimod
4. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
5. Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis
6. BD Completes Acquisition of HandyLab, Inc.
7. EDDA Technology Completes CE Mark for IQQA(R)-Liver for Fast Quantitative Volumetry Assessment from Liver MDCT
8. WellTek/MedX Group Completes Major Reorganization
9. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
10. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
11. Cell Biosciences Completes Acquisition of Alpha Innotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/19/2014)... -- PCI is pleased to announce it has acquired ... provider of Clinical Trial Services and Temperature Controlled ... in the United Kingdom ... in the UK/EU to support global investigational studies ... distribution capacity, as well as consultative services for ...
(Date:9/18/2014)... 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... of the underwriters, option to purchase 675,000 additional ... company,s previously announced public offering of 4,500,000 shares ... being offered by Aratana Therapeutics.  With the exercise ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
(Date:9/20/2014)... The Arizona Advanced Manufacturing Institute ... Manufacturing Day by opening its doors to the community. ... manufacturing labs will be offered between 10 a.m. and ... and Dobson campus (1833 W. Southern Ave, Mesa, AZ ... The AzAMI at MCC was established in the fall ...
(Date:9/19/2014)... Columbus, OH (PRWEB) September 20, 2014 ... Philadelphia Court of Common Pleas where a meeting took ... Risperdal side-effects complaints pending in the court’s mass ... scheduled to meet this past week at the Complex ... complaints are consolidated for pretrial proceedings. The Risperdal lawsuits ...
(Date:9/19/2014)... BearCom, a nationwide provider of wireless ... role played by instant, one-to-one and one-to-many communications ... , “In healthcare, speed of information flow ... emergency situations, can save precious seconds that can ... Hugh Johnston, Product & Purchasing Manager at BearCom. ...
(Date:9/19/2014)... working with The Melanoma Genetics Consortium, GenoMEL, an international ... Journal of the National Cancer Institute that ... "For the first time, we have established that the ... part in the risk of developing melanoma," said lead ... Medicine at the University of Leeds (UK). , ...
(Date:9/19/2014)... News) -- Your brain structure could help predict how willing ... Researchers at Yale University found those with greater volume ... cortex may be more likely to engage in risky behavior ... The study, funded by the U.S. National Institute on Aging, ... in the Northeast. The researchers sought to determine how brain ...
Breaking Medicine News(10 mins):Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4Health News:Melanoma risk found to have genetic determinant 2Health News:Brain Structure Might Help Predict Risky Behavior 2
... bundles, scientists say , , WEDNESDAY, April 15 (HealthDay News) ... in certain neural pathways of the brain to the ... finding could lead to a better understanding of the ... and coordination that characterizes this difficult-to-diagnose disorder -- also ...
... MD, April 14, 2009 -- Sleep is such an essential ... of our lives doing it -- some more successfully than ... United States and are a major cause of disease and ... risk of heart attack, stroke, hypertension, obesity, depression, and accidents. ...
... with 100% of Updated Interoperability RequirementsTAMPA, Fla., April ... provider of electronic health records, today announced that ... has approved Sage,s product, Sage Intergy EHR, ... EHR , additionally certified for Child ...
... Harvard Business School recently completed a case study ... a private nonprofit organization that helps children and families ... a national leader in the field of children,s behavioral ... Allen Grossman, Catherine Ross of the HBS Global Research ...
... AIDS for years after initial infection by HIV have ... One component of this remarkable resistance comes from an ... genes that help the immune system recognize and fight ... the Emory Vaccine Center studying HIV-infected people with particularly ...
... minimally invasive surgical approach to treat stomach cancer has ... a preferable treatment for some patients. , A new ... (MSKCC) compares traditional "open" surgery to remove the stomach ... which the surgeon removes the stomach while guided by ...
Cached Medicine News:Health News:Brain Scans Reveal Secrets of 'Writer's Cramp' 2Health News:New way to analyze sleep disorders 2Health News:New way to analyze sleep disorders 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 2Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 3Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 4Health News:HIV handicaps itself to escape immune system pressure 2Health News:New minimally invasive surgery option for patients with stomach cancer 2
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
... is a supportive .035" guide wire compatible stent system ... lengths of 18 mm, 28 mm, 38 mm and ... in 12 and 16 mm lengths. The 4.0 ... Two "diameter specific" OMNILINK® stents were developed - one ...
... particular challenge in transseptal left heart catheterization ... be exchanged for a sheath with an ... position. Traditionally, such an exchange has required ... patient. Biosense Webster has overcome this problem ...
... Jude Medical's line of guiding introducers ... RAMP, and 2 piece steerable, all ... catheters when the varying curves and ... physician technique. St. Jude Medical guiding ...
Medicine Products: